<DOC>
	<DOCNO>NCT02367794</DOCNO>
	<brief_summary>This randomize , open-label study evaluate safety efficacy atezolizumab ( MPDL3280A ) combination carboplatin + paclitaxel carboplatin + nab-paclitaxel compare treatment carboplatin + nab-paclitaxel chemotherapy- naive participant Stage IV squamous NSCLC .</brief_summary>
	<brief_title>A Study Atezolizumab Combination With Carboplatin + Paclitaxel Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel Participants With Stage IV Squamous Non-small Cell Lung Cancer ( NSCLC ) IMpower 131</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically cytologically confirm , treatmentna√Øve Stage IV squamous NSCLC Previously obtain archival tumor tissue tissue obtain biopsy screen Measurable disease define RECIST v1.1 Adequate hematologic end organ function Active untreated central nervous system ( CNS ) metastasis Malignancies NSCLC within 5 year prior randomization , exception negligible risk metastasis death treat expect curative outcome Pregnant lactate woman History autoimmune disease History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest Computed Tomography ( CT ) scan , History radiation pneumonitis radiation field ( fibrosis ) permit Positive test Human Immunodeficiency Virus ( HIV ) Active hepatitis B hepatitis C Prior treatment cluster differentiation 137 ( CD137 ) agonists immune checkpoint blockade therapy , antiprogrammed death1 ( antiPD1 ) , antiprogrammed deathligand 1 ( antiPDL1 ) therapeutic antibody Severe infection within 4 week prior randomization Significant history cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>